Drug Trial Radar · NCT06449001
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Aug 11, 2025
Primary completion
May 28, 2027
Study completion Mar 10, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Jun 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- PNH
- Extravascular Hemolysis
Interventions
DanicopanDrug
Participants will receive danicopan on a weight-based dosing regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin (Hgb) Concentration at Week 12Time frame: Baseline, Week 12
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Saskatoon, Saskatchewan, Canada · Recruiting
Research Site
Paris, France · Recruiting
Research Site
Leeds, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.